Trial Profile
Phase IIb trial investigating the efficacy of KRN 5500 in patients with chronic chemotherapy-induced neuropathic pain.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 15 Aug 2013
Price :
$35
*
At a glance
- Drugs KRN 5500 (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- 18 Jan 2012 Planned initiation date changed from 1 Jul 2010 to 1 Jun 2012.
- 25 Mar 2010 This trial is expected to be initiated in the second half of 2010 according to a Dara BioScience media release.
- 27 Nov 2009 New trial record.